Thyrocare promoter Docon Technologies sells 10% stake for Rs 668 crore; stock up 1.6%

Thyrocare Technologies Ltd on Friday said that its promoter Docon Technologies Pvt Ltd sold about 10 percent of the company’s equity stake in open market transactions for Rs 667.69 crore.

Docon sold 53.33 lakh shares of Thyrocare on October 24 at an average price of about Rs 1,252.03 per share, according to a disclosure made by the company to the exchanges. Following the sale, Docon’s shareholding in Thyrocare has fallen to 60.93 percent from 70.98 percent earlier. The company clarified that Docon continues to remain a promoter even after this transaction.

Thyrocare stock rose 1.62 percent to Rs 1,272.20 on Friday, valuing the diagnostics chain at about Rs 6,700 crore. The stock has gained over 50 percent in the past six months and trades near the upper end of its 52-week range of Rs 658 to Rs 1,474.

• Also read | Thyrocare net profit jumps 80% to Rs 48 crore in Q2, firm announces 2:1 bonus issue

The stock has a P/E ratio of 52.8, which is slightly higher than the sector P/E of 50.54, according to Moneycontrol data. Thyrocare stock has a dividend yield of 1.65 percent.

The deal was executed through market trades and will be settled as per applicable regulations, Thyrocare said in its filing.

Earlier this month, Thyrocare Technologies reported a strong financial performance for Q2 FY26, with net profit surging 80 percent year-on-year to Rs 48 crore, compared with Rs 27 crore in the same period last year. Revenue from operations rose over 22 percent to Rs 216.53 crore, while consolidated EBITDA climbed 48 percent, with margins at 33 percent. The diagnostics chain also announced a 2:1 bonus issue of shares alongside its quarterly results.